Large Volume Wearable Injectors Market (4th Edition), 2018-2030

ALHAMBRA, Calif. - April 29, 2020 - PRLog -- Harsimran Kaur, the principal analyst, stated, "The large volume wearable injectors continue to retain the interest of both drug developers and medical device manufacturers. This can be attributed to the various benefits offered by these devices. In fact, over 50 devices are currently under development / approved for the delivery of both insulin and non-insulin drugs."

The report presents opinions on several key aspects of the market. Among other elements, it includes:

• A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It is worth highlighting that devices designed for administration of non-insulin drugs have a high storage capacity and are being developed for delivery of high viscosity formulations. In fact, around 17% of such devices have been designed to hold 10-15 ml of drug formulation, while 23% claim to offer a maximum storage capacity of more than 15 ml.
• A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). Close to 80 drug / drug candidates demonstrate the potential to be delivered via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. Of these, 90% are biologics and 10% are small molecules. These drugs (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems.
• A comprehensive product competitiveness analysis of all large volume wearable injectors, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application, and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
https://www.rootsanalysis.com/